<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autoinflammatory diseases mediated by miscellaneous mechanisms</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autoinflammatory diseases mediated by miscellaneous mechanisms</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autoinflammatory diseases mediated by miscellaneous mechanisms</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Nigrovic, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1706445675"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autoinflammatory diseases are conditions of pathogenic chronic or recurrent inflammation mediated by antigen-independent hyperactivation of the immune system [<a href="#rid1">1</a>]. Most represent inborn errors of immunity. A broad spectrum of autoinflammatory diseases is now recognized, differing markedly from one another in pathogenesis and clinical manifestations.</p><p>This topic review covers autoinflammatory diseases via mechanisms beyond those covered in other specific topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever"</a> and  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5956.html" rel="external">"Hyperimmunoglobulin D syndrome: Pathophysiology"</a> and  <a class="medical medical_review" href="/d/html/5954.html" rel="external">"Hyperimmunoglobulin D syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5955.html" rel="external">"Hyperimmunoglobulin D syndrome: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5580.html" rel="external">"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/122506.html" rel="external">"Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/122508.html" rel="external">"Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/132472.html" rel="external">"Deficiency of adenosine deaminase 2 (DADA2)"</a>.)</p><p></p><p>A general discussion of autoinflammatory diseases is available separately, as are topics on classification and genetic diagnosis of inborn errors of immunity:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/117758.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Classification"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/116805.html" rel="external">"Genetic testing in patients with a suspected primary immunodeficiency or autoinflammatory syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H2924980898"><span class="h1">OVERVIEW OF PATHOGENESIS</span><span class="headingEndMark"> — </span>Normal immune function requires that inflammatory pathways are activated when needed for host defense, but that activation is limited to the intensity, location, and duration required to clear the threat in order to minimize damage to healthy tissues. To achieve this end, multiple negative regulatory loops are in place to constrain and ultimately shut down proinflammatory pathways. Dysfunction in these mechanisms can result in autoinflammation. Examples discussed elsewhere include variants in <em>MEFV</em> that render the protein pyrin resistant to control through phosphorylation, leading to familial Mediterranean fever (see  <a class="medical medical_review" href="/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"</a>); variants in ubiquitin-specific peptidase 18 (<em>USP18</em>) that intensify interferon (IFN) receptor signals, resulting in an interferonopathy termed pseudo-TORCH (toxoplasmosis, other [syphilis], rubella, cytomegalovirus, herpes simplex virus) syndrome (see  <a class="medical medical_review" href="/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)", section on 'Pseudo-TORCH syndrome'</a>); and aberrant activation of proinflammatory transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) through deficiency of the key regulatory protein A20. (See  <a class="medical medical_review" href="/d/html/122508.html" rel="external">"Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity", section on 'Haploinsufficiency of A20'</a>.)</p><p>Here, we discuss autoinflammatory disorders that do not fit comfortably into any of the broad autoinflammatory disease categories or define their own. These disorders arise from deficiency of adenosine deaminase 2 (ADA2), defects in vesicle trafficking (COPA syndrome), and pathogenic variants affecting phospholipase C gamma 2 (PLCG2), or transfer RNA (tRNA) nucleotidyltransferase, CCA-adding 1 (TRNT1).</p><p class="headingAnchor" id="H1519499890"><span class="h1">SPECIFIC AUTOINFLAMMATORY DISORDERS</span></p><p class="headingAnchor" id="H1393469372"><span class="h2">COPA syndrome</span><span class="headingEndMark"> — </span>Pathogenic variants in the coatomer protein complex, subunit alpha gene (<em>COPA</em>) result in a syndrome featuring interstitial lung disease, pulmonary hemorrhage, and inflammatory arthritis (see  <a class="medical medical_review" href="/d/html/6374.html" rel="external">"Approach to the infant and child with diffuse lung disease (interstitial lung disease)", section on 'Genetic testing'</a>) [<a href="#rid2">2,3</a>]. Patients may have autoantibodies including rheumatoid factor, anti-cyclic citrullinated peptide (CCP), antinuclear antibody (ANA), and antineutrophil cytoplasmic antibody (ANCA). Peripheral blood analysis reveals an interferon gene signature [<a href="#rid4">4</a>]. How this signature arises remains unclear.</p><p>COPA helps to transport vesicles from the Golgi apparatus to the endoplasmic reticulum. This vesicular movement, retrograde with respect to the normal flow of protein synthesis and secretion, limits endoplasmic reticulum accumulation of the protein stimulator of interferon genes (STING), a key molecule in the detection of intracellular DNA viruses. Deficiency of COPA results in excess STING signaling and thereby aberrant production of type I interferons [<a href="#rid5">5</a>]. This close relationship between COPA and STING helps explain the clinical similarity between COPA syndrome and STING-associated vasculopathy with onset in infancy (SAVI). More generally, aberrant vesicular trafficking promotes inflammation through inadequate protein processing, triggering the cell's unfolded protein response [<a href="#rid2">2</a>]. Studies in an animal model implicate defects in T cell education in the thymus, as well as defects in regulatory T cells, resulting in lung damage mediated directly by pathogenic T cells and blurring the border between autoinflammation and autoimmunity [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)", section on 'STING-associated vasculopathy with onset in infancy (SAVI)'</a>.)</p><p>Response to Janus kinase (JAK) inhibitor treatment is reported, and glucocorticoids and other immunosuppressive agents provide some benefit [<a href="#rid7">7-10</a>].</p><p class="headingAnchor" id="H2632116345"><span class="h2">PLAID/APLAID</span><span class="headingEndMark"> — </span>Autoinflammation and phospholipase C gamma 2 (PLCG2) associated antibody deficiency and immune dysregulation (APLAID) and PLAID (also called familial cold autoinflammatory syndrome 3 [FCAS3], a form of familial atypical cold urticaria) are caused by different heterozygous pathogenic variants of the <em>PLCG2</em> gene [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a> and  <a class="medical medical_review" href="/d/html/8102.html" rel="external">"Cold urticaria", section on 'Atypical forms of cold urticaria'</a>.)</p><p>The autoinflammation in PLAID manifests as pruritic erythema with urticaria and sometimes angioedema elicited by evaporative cooling (eg, exposure to cold air or wind) rather than touching cold objects or water [<a href="#rid11">11</a>]. Neonatal skin findings include ulcers and other lesions in cold-sensitive regions (nose, fingers, toes, cheeks) and granulomatous lesions that spare warm regions (flexural areas, skin folds) [<a href="#rid13">13</a>]. Cold-induced leukocyte activation is also seen. Autoimmunity and immunodeficiency (antibody/B cell and natural killer [NK] cell defects) are each present in approximately one-half of patients.</p><p>APLAID is characterized by recurrent blistering skin lesions, ocular inflammation, enterocolitis, bronchiolitis, arthralgia, and mild immunodeficiency [<a href="#rid12">12</a>].</p><p>Treatment of PLAID and APLAID is not well established. PLAID symptoms can be ameliorated partially through avoidance of evaporative cooling (eg, by toweling off rapidly after exercise or showering) as well as antihistamines [<a href="#rid14">14</a>]. Environmental triggers for APLAID are not well defined. Glucocorticoids improve APLAID-associated inflammation, but usage is limited by side effects. Partial response to interleukin (IL) 1 blockade was reported in one family but not in another [<a href="#rid12">12,15</a>].</p><p class="headingAnchor" id="H3786667409"><span class="h2">SIFD syndrome</span><span class="headingEndMark"> — </span>Congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD) is caused by hypomorphic biallelic variants in the tRNA nucleotidyl transferase 1 (<em>TRNT1</em>) gene, encoding the enzyme tRNA nucleotidyltransferase, CCA-adding 1, that lead to dysregulation in protein clearance pathways [<a href="#rid16">16,17</a>]. TRNT1 is ubiquitously and constitutively expressed. Patients with SIFD have increased levels of IL-6 and interferon (IFN) gamma in the serum and TNF and IL-1-beta in tissue biopsies. Mitochondrial dysfunction is also seen.</p><p>The spectrum of clinical features is broad and includes [<a href="#rid16">16,18-21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever that typically lasts five to seven days</p><p class="bulletIndent1"><span class="glyph">●</span>Mucocutaneous (oral ulcers, cellulitis) manifestations</p><p class="bulletIndent1"><span class="glyph">●</span>Musculoskeletal (arthralgias, arthritis, dactylitis) manifestations</p><p class="bulletIndent1"><span class="glyph">●</span>Sideroblastic or aplastic anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Immunodeficiency of variable severity (hypogammaglobulinemia most common; B cells low, with decreased mature cells, to normal; T and NK cells also low to normal; serious bacterial and viral infections rare)</p><p class="bulletIndent1"><span class="glyph">●</span>Enteropathy</p><p class="bulletIndent1"><span class="glyph">●</span>Vision and sensorineural hearing loss</p><p class="bulletIndent1"><span class="glyph">●</span>Developmental delay, neurodegeneration, seizures, and cerebellar abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Failure to thrive</p><p></p><p>Severity can range from profound anemia, severe immunodeficiency, hemophagocytic lymphohistiocytosis, and metabolic abnormalities with death in early childhood to milder forms with retinitis pigmentosa and more moderate hematologic and immunologic defects. Median survival is 48 months. Complete deficiency of TRNT1 is embryonic lethal. (See  <a class="medical medical_review" href="/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (TRNT1 mutation)'</a>.)</p><p>Several patients have been successfully treated with TNF inhibitors (<a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>), with suppression of fevers, improvement in other clinical manifestations, and normalization of elevated acute-phase reactants and proinflammatory cytokines and chemokines [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H383533547"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Autoinflammatory diseases should be considered in patients who present with inflammatory episodes that recur or persist over months or years in the absence of other causes. Unusual infections and malignancy are first excluded. The evaluation then proceeds with an attempt to identify a clinical pattern consistent with one of the known autoinflammatory disorders (<a class="graphic graphic_table graphicRef130004" href="/d/graphic/130004.html" rel="external">table 1</a>). Genetic testing remains the mainstay of diagnosis, either targeted to a single gene or, more commonly, to a panel of autoinflammation-associated diseases.</p><p>The disorders considered in this topic should be considered for patients who develop some combination of the following symptoms, especially beginning in childhood:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coatomer protein complex subunit alpha (COPA) syndrome</strong> – Interstitial lung disease, pulmonary hemorrhage, arthritis, autoantibodies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PLCG2-associated antibody deficiency and immune dysregulation (PLAID)/autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID)</strong> – Cold-induced urticaria, acral blistering lesions, humoral immunodeficiency, tissue-focused inflammation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD)</strong> – Fever, anemia, retinitis, skin and joint inflammation</p><p></p><p class="headingAnchor" id="H734128259"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of the autoinflammatory diseases reviewed here includes other autoinflammatory diseases, for example, mediated through inflammasomes, interferon, or nuclear factor kappa B (NFkB)/tumor necrosis factor (TNF) (<a class="graphic graphic_table graphicRef130004" href="/d/graphic/130004.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview", section on 'Diagnosis'</a>.)</p><p>Other inflammatory diseases to be considered include multicentric Castleman disease and autoimmune lymphoproliferative syndrome (ALPS). (See  <a class="medical medical_review" href="/d/html/117312.html" rel="external">"HHV-8-negative/idiopathic multicentric Castleman disease"</a> and  <a class="medical medical_review" href="/d/html/16837.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis"</a>.)</p><p>The differential diagnosis also includes unusual infections such as relapsing fever, malignancy and premalignant states (Schnitzler syndrome), cyclic neutropenia, and rheumatic diseases including systemic juvenile idiopathic arthritis (sJIA)/adult-onset Still's disease (AOSD). (See  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5996.html" rel="external">"Fever of unknown origin in children: Etiology"</a> and  <a class="medical medical_review" href="/d/html/5993.html" rel="external">"Fever of unknown origin in children: Evaluation"</a> and  <a class="medical medical_review" href="/d/html/2737.html" rel="external">"Fever of unknown origin in adults: Etiologies"</a> and  <a class="medical medical_review" href="/d/html/2736.html" rel="external">"Fever of unknown origin in adults: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H1643464234"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of the autoinflammatory diseases discussed here varies with condition (see discussions on each specific autoinflammatory disorder above). Therapies for coatomer protein complex subunit alpha (COPA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID)/autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID), and sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD) are less well established, and patients respond variably to glucocorticoids, tumor necrosis factor (TNF) inhibitors, Janus kinase (JAK) inhibitors, or other interventions.</p><p class="headingAnchor" id="H4292451734"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – The autoinflammatory diseases (<a class="graphic graphic_table graphicRef130004" href="/d/graphic/130004.html" rel="external">table 1</a>) constitute a family of disorders characterized by aberrant activation of inflammatory pathways in the absence of antigen-directed autoimmunity. Most forms of autoinflammatory disease represent inborn errors of immunity. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and specific disorders</strong> – Some autoinflammatory diseases are mediated by mechanisms that do not fall comfortably within the major families of autoinflammatory disorders. These include coatomer protein complex subunit alpha (COPA) syndrome, PLCG2-associated antibody deficiency and immune dysregulation (PLAID)/autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID), and sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). (See <a class="local">'Overview of pathogenesis'</a> above and <a class="local">'Specific autoinflammatory disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– Autoinflammatory diseases should be considered in patients who present with inflammatory episodes that recur or persist over months or years in the absence of other causes. After excluding unusual infections and malignancy, the next step is to attempt to identify a clinical pattern consistent with one of the known autoinflammatory disorders (<a class="graphic graphic_table graphicRef130004" href="/d/graphic/130004.html" rel="external">table 1</a>). Genetic testing remains the mainstay of diagnosis. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of autoinflammatory diseases includes unusual infections such as relapsing fever, malignancy and premalignant states (Schnitzler syndrome), cyclic neutropenia, and rheumatic diseases including systemic juvenile idiopathic arthritis (sJIA)/adult-onset Still's disease (AOSD). (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatments for COPA syndrome, PLAID/APLAID, and SIFD are not well established. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol 2020; 146:925.</a></li><li><a class="nounderline abstract_t">Watkin LB, Jessen B, Wiszniewski W, et al. COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat Genet 2015; 47:654.</a></li><li><a class="nounderline abstract_t">Vece TJ, Watkin LB, Nicholas S, et al. Copa Syndrome: a Novel Autosomal Dominant Immune Dysregulatory Disease. J Clin Immunol 2016; 36:377.</a></li><li><a class="nounderline abstract_t">Volpi S, Tsui J, Mariani M, et al. Type I interferon pathway activation in COPA syndrome. Clin Immunol 2018; 187:33.</a></li><li><a class="nounderline abstract_t">Uggenti C, Lepelley A, Crow YJ. Self-Awareness: Nucleic Acid-Driven Inflammation and the Type I Interferonopathies. Annu Rev Immunol 2019; 37:247.</a></li><li><a class="nounderline abstract_t">Deng Z, Law CS, Ho FO, et al. A Defect in Thymic Tolerance Causes T Cell-Mediated Autoimmunity in a Murine Model of COPA Syndrome. J Immunol 2020; 204:2360.</a></li><li><a class="nounderline abstract_t">Tsui JL, Estrada OA, Deng Z, et al. Analysis of pulmonary features and treatment approaches in the COPA syndrome. ERJ Open Res 2018; 4.</a></li><li><a class="nounderline abstract_t">Frémond ML, Legendre M, Fayon M, et al. Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage. Thorax 2020; 75:92.</a></li><li><a class="nounderline abstract_t">Krutzke S, Rietschel C, Horneff G. Baricitinib in therapy of COPA syndrome in a 15-year-old girl. Eur J Rheumatol 2020; 7:S78.</a></li><li><a class="nounderline abstract_t">Guan Y, Liu H, Tang X, et al. Effective sirolimus treatment of 2 COPA syndrome patients. J Allergy Clin Immunol Pract 2021; 9:999.</a></li><li><a class="nounderline abstract_t">Ombrello MJ, Remmers EF, Sun G, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012; 366:330.</a></li><li><a class="nounderline abstract_t">Zhou Q, Lee GS, Brady J, et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 2012; 91:713.</a></li><li><a class="nounderline abstract_t">Aderibigbe OM, Priel DL, Lee CC, et al. Distinct Cutaneous Manifestations and Cold-Induced Leukocyte Activation Associated With PLCG2 Mutations. JAMA Dermatol 2015; 151:627.</a></li><li><a class="nounderline abstract_t">Milner JD. PLAID: a Syndrome of Complex Patterns of Disease and Unique Phenotypes. J Clin Immunol 2015; 35:527.</a></li><li><a class="nounderline abstract_t">Neves JF, Doffinger R, Barcena-Morales G, et al. Novel PLCG2 Mutation in a Patient With APLAID and Cutis Laxa. Front Immunol 2018; 9:2863.</a></li><li><a class="nounderline abstract_t">Chakraborty PK, Schmitz-Abe K, Kennedy EK, et al. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood 2014; 124:2867.</a></li><li><a class="nounderline abstract_t">Sasarman F, Thiffault I, Weraarpachai W, et al. The 3' addition of CCA to mitochondrial tRNASer(AGY) is specifically impaired in patients with mutations in the tRNA nucleotidyl transferase TRNT1. Hum Mol Genet 2015; 24:2841.</a></li><li><a class="nounderline abstract_t">Hull S, Malik AN, Arno G, et al. Expanding the Phenotype of TRNT1-Related Immunodeficiency to Include Childhood Cataract and Inner Retinal Dysfunction. JAMA Ophthalmol 2016; 134:1049.</a></li><li><a class="nounderline abstract_t">DeLuca AP, Whitmore SS, Barnes J, et al. Hypomorphic mutations in TRNT1 cause retinitis pigmentosa with erythrocytic microcytosis. Hum Mol Genet 2016; 25:44.</a></li><li><a class="nounderline abstract_t">Frans G, Moens L, Schaballie H, et al. Homozygous N-terminal missense mutation in TRNT1 leads to progressive B-cell immunodeficiency in adulthood. J Allergy Clin Immunol 2017; 139:360.</a></li><li><a class="nounderline abstract_t">Sharma TP, Wiley LA, Whitmore SS, et al. Patient-specific induced pluripotent stem cells to evaluate the pathophysiology of TRNT1-associated Retinitis pigmentosa. Stem Cell Res 2017; 21:58.</a></li><li><a class="nounderline abstract_t">Giannelou A, Wang H, Zhou Q, et al. Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors. Ann Rheum Dis 2018; 77:612.</a></li></ol></div><div id="topicVersionRevision">Topic 122509 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33160483" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25894502" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27048656" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Copa Syndrome: a Novel Autosomal Dominant Immune Dysregulatory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29030294" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Type I interferon pathway activation in COPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30633609" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Self-Awareness: Nucleic Acid-Driven Inflammation and the Type I Interferonopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32198142" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A Defect in Thymic Tolerance Causes T Cell-Mediated Autoimmunity in a Murine Model of COPA Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29977900" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Analysis of pulmonary features and treatment approaches in the COPA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31666386" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31449490" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Baricitinib in therapy of COPA syndrome in a 15-year-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33099043" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effective sirolimus treatment of 2 COPA syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22236196" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000145" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25760457" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Distinct Cutaneous Manifestations and Cold-Induced Leukocyte Activation Associated With PLCG2 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26206677" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : PLAID: a Syndrome of Complex Patterns of Disease and Unique Phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30619256" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Novel PLCG2 Mutation in a Patient With APLAID and Cutis Laxa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25193871" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25652405" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The 3' addition of CCA to mitochondrial tRNASer(AGY) is specifically impaired in patients with mutations in the tRNA nucleotidyl transferase TRNT1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27389523" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Expanding the Phenotype of TRNT1-Related Immunodeficiency to Include Childhood Cataract and Inner Retinal Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26494905" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hypomorphic mutations in TRNT1 cause retinitis pigmentosa with erythrocytic microcytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27531075" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Homozygous N-terminal missense mutation in TRNT1 leads to progressive B-cell immunodeficiency in adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28390992" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Patient-specific induced pluripotent stem cells to evaluate the pathophysiology of TRNT1-associated Retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29358286" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
